<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553915</url>
  </required_header>
  <id_info>
    <org_study_id>R01AT008857-01</org_study_id>
    <nct_id>NCT02553915</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach</brief_title>
  <official_title>Omega-3 Fatty Acids for MDD With High Inflammation: A Personalized Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to evaluate whether a dose-response relationship exists between dose of
      polyunsaturated fatty acids (PUFA), delivered as eicosapentaenoic acid (EPA), and change in
      markers of inflammation, and whether these effects differ from placebo. A key secondary aim
      is to evaluate the antidepressant effectiveness of EPA in overweight adult outpatients with
      current major depressive disorder (MDD). To address these aims, the project will use a
      four-arm, randomized, parallel-group, placebo-controlled design comparing placebo versus
      three doses of EPA (1 gm/day, 2 gm/day, or 4 gm/day) administered over 12 weeks. The study is
      to be conducted at two sites: Emory University School of Medicine, and Massachusetts General
      Hospital. Eligible participants will be between the ages of 18-80 who have current MDD, are
      overweight, and who demonstrate peripheral inflammation, defined as an high sensitivity
      C-reactive protein (hs-CRP) level ≥ 3 mg/L. The primary outcome will be change in plasma
      interleukin-6 (IL-6) levels and/or mitogen-stimulated peripheral blood mononuclear cells
      (PBMC) Tumor Necrosis Factor-alpha (TNF-α) expression levels in EPA- versus placebo-treated
      participants. The results of this investigation are intended to be used to design and power a
      larger definitive test of the efficacy and biological effects of EPA in patients with major
      depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the anti-inflammatory effects and antidepressant efficacy and
      tolerability of EPA versus placebo in the treatment of MDD. The study design is a randomized,
      placebo-controlled, double-blind parallel-group dose-finding 12 week outpatient clinical
      trial. The study population will consist of outpatients who are overweight and suffer from
      MDD, who also demonstrate systemic inflammation. Three doses of EPA (1 gm/d, 2 gm/d, and 4
      gm/d) will be compared against placebo. The study will be conducted at two sites: Emory
      University School of Medicine and Massachusetts General Hospital. The study will be conducted
      under the Food and Drug Administration Investigational New Drug (IND) 074150.

      One hundred adult MDD patients (ages 18-80) will be randomized to enter the 12-week
      double-blind treatment period. Each of the four study arms (3 EPA arms and one placebo arm)
      will have 25 patients, with the expectation of 20 completers per arm, based on a 20% early
      termination rate. The subjects will be recruited through advertisements and clinical
      referrals from psychiatrists and general physicians who are treating overweight outpatients
      with MDD. Participants must agree not to significantly modify their diet during the 12 weeks
      of the study.

      Due to the need for participants to have a hs-CRP ≥ 3 mg/L to be eligible for the study, two
      screening visits will be used to minimize expenses associated with screening. The screening
      period may extend up to 28 days prior to the baseline visit (Visit 3) if necessary to allow
      for time need for participant scheduling and allow for any required repeat laboratory
      testing.

      Patients screened for the study and found to be eligible will return for their baseline visit
      after one week, during which no psychotropic medication or PUFAs will be administered.
      Patients must have an Inventory of Depressive Symptoms, Clinician rated (IDS-C30) total score
      ≥ 25 at the baseline visit in order to be eligible for randomization.

      Patients will be randomized to one of four treatment arms: 1) EPA 1 mg/day; 2) EPA 2 mg/day;
      3) EPA 4 mg/day; or 4) Placebo. Randomization will be in blocks of 4 with separate
      randomization schedules for each site.

      Study materials will include:

        1. Study capsules containing EPA-enriched omega-3, 1000 mg tabs, supplied by Nordic
           Naturals.

        2. Placebo capsules matching the EPA 1000 mg tabs, also to be supplied by Nordic Naturals.

      Documentation of the presence of any side-effect or adverse event (AE) will be completed by
      one of the treating psychiatrists at every visit by recording all spontaneously reported AEs,
      which will be classified as either mild, moderate, or severe. Adverse events will be coded
      using Medical Dictionary for Regulatory Activities (MedDRA) terms. Patients shall be allowed
      to contact the investigator or a member of his staff at any time between visits concerning
      adverse events or worsening of symptoms.

      All concomitant medications taken during the study will be recorded in the case report form,
      along with dosage information and start and stop dates. Drugs that may be taken by the
      patient include any prescription or over-the-counter medication not specifically excluded by
      the protocol. Patients requiring excluded drugs (including antidepressants, benzodiazepines,
      antipsychotics, psychostimulants, and mood stabilizing agents) will be discontinued from the
      study.

      Patients may choose to withdraw from the study at any time.

      Participants may be withdrawn by the investigator should any of the following occur:

        1. severe, persistent intolerance to study medication

        2. worsening of depressive symptoms such that the subject's safety is endangered (e.g.
           suicidality)

        3. development of mania or psychotic symptoms

        4. a serious adverse event (SAE) that is either: i) considered by the investigator to be
           possibly, probably, or definitely related to the study medication, or ii) places the
           subject at increased risk of harm if she were to continue in the study

        5. persistent non-adherence to the study medication, defined as not taking between 80-120%
           of the study medication pills for two consecutive visits

        6. development of pregnancy

      Patients with MDD may experience worsening of their depression and/or the emergence of
      suicidal ideation and behavior (suicidality), whether or not they are taking antidepressant
      medications, and this risk may persist until MDD remission occurs. This guidance is
      consistent with global class labelling for antidepressants. Although there has been a
      long-standing concern that antidepressants may have a role in inducing worsening of
      depression and the emergence of suicidality in certain subjects, a causal role for
      antidepressants in inducing such behaviors has not been established. Nevertheless, subjects
      being treated with study medication will be observed closely for clinical worsening and
      suicidality, especially at the beginning and end of the course of treatment, or at the time
      of dose changes, either increases or decreases. Consideration will be given to possibly
      discontinuing the investigational product in subjects whose depression is persistently worse
      or whose emergent suicidality is severe or abrupt in onset or was not part of the subject's
      presenting symptoms. To assess suicidal ideation and behaviors, the CSSRS will be used in
      this trial.

      The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility,
      impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported
      in patients being treated with antidepressants for MDD. Consideration will be given to
      possibly discontinuing the study medication in subjects for whom such symptoms are severe,
      abrupt in onset, or were not part of the subject's presenting symptoms.

      Research participants are exited from the study should any of the following occur:

        -  Any emergent Columbia Suicide Severity Rating Scale (CSSRS) defined suicidal behavior

        -  A suicidal ideation score of 5 (indicating active suicidal ideation with specific plan
           and some level of intent) on the CSSRS

        -  In the absence of a CSSRS suicidal ideation score of 5 or CSSRS-defined suicidal
           behavior, the investigator determines the patient to have a significant short-term risk
           for a suicide attempt.

      Any participant who becomes pregnant during the study will be withdrawn from the study. The
      investigator will collect pregnancy information, record it on the Pregnancy Form, and submit
      it to the lead site PI, Mark Rapaport, MD, via email within 2 weeks of learning of a
      participant's pregnancy. The participant will also be followed to determine the outcome of
      the pregnancy. Follow-up is expected to end approximately 8 weeks following the estimated
      delivery date. Any premature termination of the pregnancy will be reported. While pregnancy
      itself is not considered to be an adverse event (AE) or SAE, any pregnancy complication or
      elective termination of a pregnancy for medical reasons will be recorded as an AE. A
      spontaneous abortion is always considered an SAE and will be reported as such.

      All randomized participants who terminate the trial prior to the Week 12 visit will be asked
      to return for an early termination visit. The study team should complete all the Week 12
      assessments at the study termination visit. All subjects who complete the trial or
      discontinue because of lack of response or side effects will receive treatment as clinically
      appropriate and will then be referred for appropriate follow-up care.

      Blood will be collected and analyzed for the screening tests and biomarker analyses. Urine
      samples will be collected and analyzed with a toxicology screen and urinalysis. We will
      collect physical records in the form of questionnaires, phone screenings, and psychiatric
      interviews. We will request access to participants' medical records only for reasons related
      to patient safety. Participant case report forms will be kept in locked file cabinets in the
      offices of each study site.

      Biological specimens are linked to the individual patient only through a unique research
      code. All documents that directly reveal the participant's identity, such as signed consent
      forms, are stored in charts that are marked on the outside only with the participant's code
      number.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 13, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study compared 3 dosing regimens of eicosapentaenoic acid (EPA), 1 g/day, 2 g/day, and 4 g/day versus an inactive placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All the above were blinded to the interventions. Placebo and EPA capsules had identical appearances.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Plasma Concentration of Inflammatory Biomarkers IL-6 (pg/mL) and PBMC TNF-α (pg/mL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate whether a dose-response relationship exists between dose of EPA and decrease either in plasma interleukin-6 (IL-6) levels (pg/mL) or in mitogen-stimulated peripheral blood mononuclear cell (PBMC) Tumor Necrosis Factor-α (TNF-α) expression and secretion (pg/mL), when compared with placebo. Levels of inflammatory biomarkers were assessed at baseline (week 0) and at week 12 for comparison. Percent changes were calculated as relative to baseline values. Greater percent decrease indicates better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Depression Severity Score (IDS-C30) After 12 Weeks of Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate whether EPA treatment produces a decrease in ratings of depression severity after 12 weeks of treatment, when compared with placebo-treated subjects. Comparison is made between pre-treatment and post-12 weeks treatment. Inventory of Depressive Symptomatology-30 item-Clinician Rated (IDS-C30) is a depression severity scale, where lower scores indicate less depressive severity and higher scores indicate greater severity. Minimum score is 0 (zero) and maximum score is 84.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in IDS-C Score After 12 Weeks of Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate whether EPA treatment produces a decrease in ratings of depression severity, when compared with placebo-treated subjects; and whether the changes in IL-6 or mitogen- stimulated PBMC TNF-α expression will mediate changes observed in ratings of depression.
Inventory of Depressive Symptomatology-30 item-Clinician Rated (IDS-C30) is a depression severity scale, where lower scores indicate less depressive severity and higher scores indicate greater severity. Minimum score is 0 (zero) and maximum score is 84. Change in score over 12 weeks (from week 0 to week12) is calculated as a percent change from baseline. Greater percent change in the negative direction indicates better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Concentrations of Mitogen-stimulated PBMC IL-6 (pg/mL) and Plasma Tumor Necrosis Factor (TNF)-α (pg/mL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate whether EPA treatment produces decreases in plasma levels of mitogen-stimulated PBMC IL-6 and TNF-α (both in in pg/mL). Percent change calculated by comparing week 12 to week 0 (baseline). Greater decrease (change in negative direction) indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes in Levels of Expression of Inflammation-related Genes for Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)-α (in ΔΔCt Units)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate whether EPA treatment produces decreases in the expression of inflammation pathway-related genes for IL-6 and TNF-α (in ΔΔCt units). Levels compared at week 0 (baseline) and at week 12 to obtain percent change from baseline. Greater decrease (change in negative direction) indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) in mg/L</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate whether EPA treatment produces decreases in plasma hs-CRP in mg/L. Levels compared at week o (baseline) and week 12 to obtain percent change. Greater percent decrease in the negative direction indicates better outcome.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Overweight</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA 1 g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA 2 g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA 4 g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Soybean oil placebo</description>
    <arm_group_label>EPA 1 g/day</arm_group_label>
    <arm_group_label>EPA 2 g/day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPA 1 g/day</intervention_name>
    <description>Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
    <arm_group_label>EPA 1 g/day</arm_group_label>
    <other_name>Eicosapentaenoic acid; omega-3 fatty acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPA 2 g/day</intervention_name>
    <description>Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
    <arm_group_label>EPA 2 g/day</arm_group_label>
    <other_name>Eicosapentaenoic acid; omega-3 fatty acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPA 4 g/day</intervention_name>
    <description>Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
    <arm_group_label>EPA 4 g/day</arm_group_label>
    <other_name>Eicosapentaenoic acid; omega-3 fatty acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide informed consent.

          -  Men or women aged 18-80 years.

          -  A primary psychiatric diagnosis of major depressive disorder (MDD), by Diagnostic and
             Statistical Manual-5th ed (DSM-5) using the Mini International Neuropsychiatric
             Interview (MINI v.7.0).

          -  A Screening and Baseline visit Inventory of Depressive Symptoms, Clinician rated
             (IDS-C30) total score ≥ 25.

          -  Currently overweight at screening, defined as BMI &gt; 25 kg/m2.

          -  Screening visit high-sensitivity C-reactive protein concentration ≥ 3 mg/L.

          -  Willing to not significantly modify their diet from the time they sign consent through
             the end of study participation.

        Exclusion Criteria:

          -  Use of any psychotropic agents within 2 weeks of baseline or at any time during the
             study, with the exception of prescription hypnotics (eszopiclone, zaleplon, zolpidem,
             suvorexant, ramelteon), diphenhydramine, or a stable daily dose of a benzodiazepine.

          -  Breastfeeding or pregnant women, women intending to become pregnant within 6 months of
             the screening visit, or women of child bearing potential who are not using a medically
             accepted means of contraception (defined as oral contraceptive pill or implant,
             condom, diaphragm, intrauterine device (IUD), status-post tubal ligation, or partner
             with vasectomy)

          -  Patients who, in the investigator's judgement, pose a current, serious suicidal or
             homicidal risk.

          -  Serious or unstable medical illness that in the investigator's opinion could
             compromise response to treatment or interpretation of study results.

          -  History of seizure disorder, except for childhood febrile seizures.

          -  Meeting DSM-5 criteria at any point in their lifetime, for any of the following:
             Neurocognitive Disorder, Psychotic Disorder, Bipolar disorder, Anorexia Nervosa

          -  Meeting DSM-5 criteria in the 3 months prior to the screening visit for any Substance
             Use Disorder (except nicotine or caffeine).

          -  Meeting DSM-5 criteria at screening for current obsessive compulsive disorder or
             bulimia nervosa.

          -  Presence of psychotic features at any time during the current major depressive
             episode.

          -  Any conditions or medications (within 1 week of baseline or during the trial) that
             might confound the biomarker findings, including: Regular ingestion of NSAIDs or
             Cyclooxygenase-2 (COX-2) inhibitors, or any use of oral steroids, immunosuppressants,
             interferon, chemotherapy, or anticoagulants (Patients will be instructed not to take a
             nonsteroidal antiinflammatory drug (NSAID) or COX-2 inhibitor in the 24 hours prior to
             a biomarker assessment visit), Malignancy not in remission for at least 1 year, Active
             autoimmune disorder or inflammatory bowel disease, Insulin-dependent diabetes
             mellitus.

          -  History of allergy to PUFA supplements.

          -  Laboratory evidence of undiagnosed hypothyroidism or change in treatment for
             hypothyroidism in the 3 months prior to screening.

          -  Patients who have failed to respond during the course of their current major
             depressive episode to &gt;4 adequate antidepressant trials, defined as six weeks or more
             of treatment with the FDA-defined minimally effective dose.

          -  Patients who have taken a supplement of at least 1 g/day of omega 3 fatty acids for at
             least 6 weeks during the current major depressive episode.

          -  Patients who have had electroconvulsive therapy (ECT) during the current depressive
             episode or within 6 months of the screening visit.

          -  Patients who have taken supplements with omega-3 fatty acids (see Appendix A for list
             of products) within sixty (60) days of the screening visit.

          -  Patients who, at baseline, are consuming a diet that contains more than 3g/day of
             omega-3 FA, or who consume more than 3 meals of fatty fish per week.

          -  Patients who have a history of a bleeding disorder.

          -  Patients who have participated in another clinical trial of an investigational
             medication within 1 month of the screening visit.

          -  Patients who are currently in psychotherapy that was initiated within 90 days prior to
             the study screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Depression Clinical and Research Program at Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry. 2015 Jan;76(1):54-61. doi: 10.4088/JCP.14m08986.</citation>
    <PMID>25272149</PMID>
  </results_reference>
  <results_reference>
    <citation>Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2016 Jan;21(1):71-9. doi: 10.1038/mp.2015.22. Epub 2015 Mar 24.</citation>
    <PMID>25802980</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <results_first_submitted>August 23, 2019</results_first_submitted>
  <results_first_submitted_qc>October 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2019</results_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David Mischoulon, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Omega-3</keyword>
  <keyword>EPA</keyword>
  <keyword>Depression</keyword>
  <keyword>Overweight</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Eicosapentaenoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02553915/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02553915/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
        </group>
        <group group_id="P2">
          <title>EPA 1 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
        </group>
        <group group_id="P3">
          <title>EPA 2 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
        </group>
        <group group_id="P4">
          <title>EPA 4 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adults with major depressive disorder, overweight, with elevated hsCRP at baseline.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
        </group>
        <group group_id="B2">
          <title>EPA 1 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
        </group>
        <group group_id="B3">
          <title>EPA 2 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
        </group>
        <group group_id="B4">
          <title>EPA 4 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="12"/>
                    <measurement group_id="B2" value="42" spread="15"/>
                    <measurement group_id="B3" value="44" spread="15"/>
                    <measurement group_id="B4" value="46" spread="13"/>
                    <measurement group_id="B5" value="46" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown / Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Plasma Concentration of Inflammatory Biomarkers IL-6 (pg/mL) and PBMC TNF-α (pg/mL)</title>
        <description>To evaluate whether a dose-response relationship exists between dose of EPA and decrease either in plasma interleukin-6 (IL-6) levels (pg/mL) or in mitogen-stimulated peripheral blood mononuclear cell (PBMC) Tumor Necrosis Factor-α (TNF-α) expression and secretion (pg/mL), when compared with placebo. Levels of inflammatory biomarkers were assessed at baseline (week 0) and at week 12 for comparison. Percent changes were calculated as relative to baseline values. Greater percent decrease indicates better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>Study completers with available biomarker data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
          </group>
          <group group_id="O2">
            <title>EPA 1 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
          </group>
          <group group_id="O3">
            <title>EPA 2 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
          </group>
          <group group_id="O4">
            <title>EPA 4 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Concentration of Inflammatory Biomarkers IL-6 (pg/mL) and PBMC TNF-α (pg/mL)</title>
          <description>To evaluate whether a dose-response relationship exists between dose of EPA and decrease either in plasma interleukin-6 (IL-6) levels (pg/mL) or in mitogen-stimulated peripheral blood mononuclear cell (PBMC) Tumor Necrosis Factor-α (TNF-α) expression and secretion (pg/mL), when compared with placebo. Levels of inflammatory biomarkers were assessed at baseline (week 0) and at week 12 for comparison. Percent changes were calculated as relative to baseline values. Greater percent decrease indicates better outcome.</description>
          <population>Study completers with available biomarker data</population>
          <units>percentage of change in plasma levels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Change in Plasma IL-6 (pg/mL) at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="30.24"/>
                    <measurement group_id="O2" value="-1.27" spread="28.37"/>
                    <measurement group_id="O3" value="7.19" spread="32.24"/>
                    <measurement group_id="O4" value="4.45" spread="40.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Change in PBMC TNF-alpha (pg/mL) at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="45.82"/>
                    <measurement group_id="O2" value="-0.19" spread="39.63"/>
                    <measurement group_id="O3" value="10.38" spread="80.36"/>
                    <measurement group_id="O4" value="28.54" spread="56.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To evaluate whether a dose-response relationship exists between dose of EPA and decrease either in plasma IL-6 levels or in mitogen-stimulated PBMC TNF-α expression and secretion, when compared with placebo. [Time Frame: 12 weeks]. Comparisons were made within each arm pre and post 12 weeks of treatment.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Comparisons were made for each biomarker within each arm pre and post 12 weeks of treatment.</non_inferiority_desc>
            <p_value>&lt;0.10</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Depression Severity Score (IDS-C30) After 12 Weeks of Treatment</title>
        <description>To evaluate whether EPA treatment produces a decrease in ratings of depression severity after 12 weeks of treatment, when compared with placebo-treated subjects. Comparison is made between pre-treatment and post-12 weeks treatment. Inventory of Depressive Symptomatology-30 item-Clinician Rated (IDS-C30) is a depression severity scale, where lower scores indicate less depressive severity and higher scores indicate greater severity. Minimum score is 0 (zero) and maximum score is 84.</description>
        <time_frame>12 weeks</time_frame>
        <population>Study completers with available IDS-C30 data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
          </group>
          <group group_id="O2">
            <title>EPA 1 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
          </group>
          <group group_id="O3">
            <title>EPA 2 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
          </group>
          <group group_id="O4">
            <title>EPA 4 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Depression Severity Score (IDS-C30) After 12 Weeks of Treatment</title>
          <description>To evaluate whether EPA treatment produces a decrease in ratings of depression severity after 12 weeks of treatment, when compared with placebo-treated subjects. Comparison is made between pre-treatment and post-12 weeks treatment. Inventory of Depressive Symptomatology-30 item-Clinician Rated (IDS-C30) is a depression severity scale, where lower scores indicate less depressive severity and higher scores indicate greater severity. Minimum score is 0 (zero) and maximum score is 84.</description>
          <population>Study completers with available IDS-C30 data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline IDS-C30 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="10.54"/>
                    <measurement group_id="O2" value="36.14" spread="7.15"/>
                    <measurement group_id="O3" value="31.36" spread="7.12"/>
                    <measurement group_id="O4" value="31.92" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Raw change at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.6" spread="7.82"/>
                    <measurement group_id="O2" value="-12.07" spread="11.29"/>
                    <measurement group_id="O3" value="-12.73" spread="17.32"/>
                    <measurement group_id="O4" value="-16.15" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To evaluate:
whether EPA treatment produces a decrease in ratings of depression severity, when compared with placebo-treated subjects; and
whether the changes in IL-6 or mitogen- stimulated PBMC TNF-α expression mediate changes observed in ratings of depression.
[Time Frame: 12 weeks]</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.1</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in IDS-C Score After 12 Weeks of Treatment</title>
        <description>To evaluate whether EPA treatment produces a decrease in ratings of depression severity, when compared with placebo-treated subjects; and whether the changes in IL-6 or mitogen- stimulated PBMC TNF-α expression will mediate changes observed in ratings of depression.
Inventory of Depressive Symptomatology-30 item-Clinician Rated (IDS-C30) is a depression severity scale, where lower scores indicate less depressive severity and higher scores indicate greater severity. Minimum score is 0 (zero) and maximum score is 84. Change in score over 12 weeks (from week 0 to week12) is calculated as a percent change from baseline. Greater percent change in the negative direction indicates better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>Study completers with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
          </group>
          <group group_id="O2">
            <title>EPA 1 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
          </group>
          <group group_id="O3">
            <title>EPA 2 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
          </group>
          <group group_id="O4">
            <title>EPA 4 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in IDS-C Score After 12 Weeks of Treatment</title>
          <description>To evaluate whether EPA treatment produces a decrease in ratings of depression severity, when compared with placebo-treated subjects; and whether the changes in IL-6 or mitogen- stimulated PBMC TNF-α expression will mediate changes observed in ratings of depression.
Inventory of Depressive Symptomatology-30 item-Clinician Rated (IDS-C30) is a depression severity scale, where lower scores indicate less depressive severity and higher scores indicate greater severity. Minimum score is 0 (zero) and maximum score is 84. Change in score over 12 weeks (from week 0 to week12) is calculated as a percent change from baseline. Greater percent change in the negative direction indicates better outcome.</description>
          <population>Study completers with available data</population>
          <units>percentage change in score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.73" spread="25.24"/>
                    <measurement group_id="O2" value="-34.52" spread="31.51"/>
                    <measurement group_id="O3" value="-37.53" spread="50.92"/>
                    <measurement group_id="O4" value="-51.4" spread="30.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in IDS-C30 scores were compared pre and post 12 weeks of treatment with each intervention, within each arm.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Plasma Concentrations of Mitogen-stimulated PBMC IL-6 (pg/mL) and Plasma Tumor Necrosis Factor (TNF)-α (pg/mL)</title>
        <description>To evaluate whether EPA treatment produces decreases in plasma levels of mitogen-stimulated PBMC IL-6 and TNF-α (both in in pg/mL). Percent change calculated by comparing week 12 to week 0 (baseline). Greater decrease (change in negative direction) indicates better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>Study completers with available biomarker data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
          </group>
          <group group_id="O2">
            <title>EPA 1 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
          </group>
          <group group_id="O3">
            <title>EPA 2 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
          </group>
          <group group_id="O4">
            <title>EPA 4 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Concentrations of Mitogen-stimulated PBMC IL-6 (pg/mL) and Plasma Tumor Necrosis Factor (TNF)-α (pg/mL)</title>
          <description>To evaluate whether EPA treatment produces decreases in plasma levels of mitogen-stimulated PBMC IL-6 and TNF-α (both in in pg/mL). Percent change calculated by comparing week 12 to week 0 (baseline). Greater decrease (change in negative direction) indicates better outcome.</description>
          <population>Study completers with available biomarker data</population>
          <units>percentage of change in plasma levels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Change in Plasma PBMC IL-6 (pg/mL) at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" spread="78.1"/>
                    <measurement group_id="O2" value="-0.51" spread="67.93"/>
                    <measurement group_id="O3" value="101.48" spread="296.86"/>
                    <measurement group_id="O4" value="17.37" spread="65.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Change in Plasma TNF-α (pg/mL) at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.98" spread="27.99"/>
                    <measurement group_id="O2" value="0.22" spread="23.33"/>
                    <measurement group_id="O3" value="-1.95" spread="18.63"/>
                    <measurement group_id="O4" value="-10.13" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To evaluate whether EPA treatment produces decreases in mitogen-stimulated PBMC IL-6. [Time Frame: 12 weeks] Comparisons were made between pre and post treatment levels in each of the 4 treatment arms.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Exploratory.</non_inferiority_desc>
            <p_value>&lt;0.1</p_value>
            <method>Spearman Rank Order Correlation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes in Levels of Expression of Inflammation-related Genes for Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)-α (in ΔΔCt Units)</title>
        <description>To evaluate whether EPA treatment produces decreases in the expression of inflammation pathway-related genes for IL-6 and TNF-α (in ΔΔCt units). Levels compared at week 0 (baseline) and at week 12 to obtain percent change from baseline. Greater decrease (change in negative direction) indicates better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>Completers with available genetic marker data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
          </group>
          <group group_id="O2">
            <title>EPA 1 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
          </group>
          <group group_id="O3">
            <title>EPA 2 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
          </group>
          <group group_id="O4">
            <title>EPA 4 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes in Levels of Expression of Inflammation-related Genes for Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)-α (in ΔΔCt Units)</title>
          <description>To evaluate whether EPA treatment produces decreases in the expression of inflammation pathway-related genes for IL-6 and TNF-α (in ΔΔCt units). Levels compared at week 0 (baseline) and at week 12 to obtain percent change from baseline. Greater decrease (change in negative direction) indicates better outcome.</description>
          <population>Completers with available genetic marker data</population>
          <units>percentage of gene expression level</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Change in IL-6 Gene expression (ΔΔCt) at 12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.22" spread="285.65"/>
                    <measurement group_id="O2" value="1426" spread="4573"/>
                    <measurement group_id="O3" value="16.03" spread="141.26"/>
                    <measurement group_id="O4" value="20.2" spread="172.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change in TNF-α Gene expression (ΔΔCt) at 12 wks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.56" spread="316.02"/>
                    <measurement group_id="O2" value="217.46" spread="692.42"/>
                    <measurement group_id="O3" value="-36.09" spread="37.32"/>
                    <measurement group_id="O4" value="-2.27" spread="58.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To evaluate whether EPA treatment produces decreases in the expression of inflammation pathway-related genes. [Time Frame: 12 weeks] (We evaluated gene expression of IL-6 and TNF-α.)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Exploratory</non_inferiority_desc>
            <p_value>&lt;0.1</p_value>
            <method>Spearman Rank Order Correlation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) in mg/L</title>
        <description>To evaluate whether EPA treatment produces decreases in plasma hs-CRP in mg/L. Levels compared at week o (baseline) and week 12 to obtain percent change. Greater percent decrease in the negative direction indicates better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>Study completers with available biomarker data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
          </group>
          <group group_id="O2">
            <title>EPA 1 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
          </group>
          <group group_id="O3">
            <title>EPA 2 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
          </group>
          <group group_id="O4">
            <title>EPA 4 g/Day</title>
            <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) in mg/L</title>
          <description>To evaluate whether EPA treatment produces decreases in plasma hs-CRP in mg/L. Levels compared at week o (baseline) and week 12 to obtain percent change. Greater percent decrease in the negative direction indicates better outcome.</description>
          <population>Study completers with available biomarker data</population>
          <units>percentage of change in plasma levels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" spread="54.27"/>
                    <measurement group_id="O2" value="-9.52" spread="53.87"/>
                    <measurement group_id="O3" value="1.09" spread="74.46"/>
                    <measurement group_id="O4" value="-17.96" spread="35.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded only if they emerged or worsened during the course of the study. Each patient was treated in the double blind protocol for 12 weeks. During this time, adverse events were inquired about and recorded as endorsed by patients.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Soybean oil placebo capsules, 4 capsules daily for 12 weeks
Placebo: Soybean oil placebo</description>
        </group>
        <group group_id="E2">
          <title>EPA 1 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 1 g/day: Omega-3 fatty acid extracted from fish oil, 1 g/day</description>
        </group>
        <group group_id="E3">
          <title>EPA 2 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
Placebo: Soybean oil placebo
EPA 2 g/day: Omega-3 fatty acid extracted from fish oil, 2 g/day</description>
        </group>
        <group group_id="E4">
          <title>EPA 4 g/Day</title>
          <description>Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
EPA 4 g/day: Omega-3 fatty acid extracted from fish oil, 4 g/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Acute conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Propulsive movement of large bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Acute vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Belching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation alternating with diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea/Loose stool</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastric reflux</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased frequency of bowel movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy symptoms (environmental)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hematoma (toe)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ligament strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lower limb numbness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hand laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness of unknown cause</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Acute Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn injury (right thumb)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Smaller than projected sample due to challenges in recruitment led to smaller analyzable treatment arms. Results should be considered preliminary.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr David Mischoulon, Director, Depression Clinical and Research Program, MGH</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-5198</phone>
      <email>dmischoulon@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

